Hunger was never a willpower problem. It was biology.
For generations, the struggle with weight has been cast as a failure of will — a private moral shortcoming worn publicly on the body. A Dublin-based medical start-up called Beyondbmi, emerging from University College Dublin with €525,000 in fresh funding, is challenging that framing at its root, arguing that obesity is a biological condition shaped by hormones and brain chemistry, not character. In doing so, it joins a quiet but accelerating shift in how medicine understands one of the modern world's most widespread and stigmatised conditions.
- Ireland's obesity rates have reached epidemic levels by WHO standards, yet the dominant cultural response has long been to tell people to try harder — a prescription that research shows fails most people and leaves lasting psychological damage.
- Beyondbmi's platform combines GLP-1 appetite-regulating drugs with nutritional therapy and one-to-one clinical coaching, a model that produced an average 15% body weight loss over roughly a year in US trials.
- The December 2022 funding round was oversubscribed, drawing a cohort of senior Irish business figures, signalling that investor appetite for medically-grounded obesity solutions is outpacing the old wellness-and-willpower market.
- The company will use the capital to launch in Ireland, building clinical infrastructure — health assessments, video consultations, quarterly reviews, and a proprietary app — around the drugs rather than simply dispensing them.
- With JP Morgan projecting the global obesity drug market will exceed $50 billion annually by 2030, Beyondbmi is racing to establish itself as a full-service clinical platform before the sector becomes crowded.
Dr Harriet Treacy spent years watching patients in her clinic — people managing high blood pressure, diabetes, infertility — blame themselves for weight their bodies were biologically predisposed to hold onto. The hunger they felt, she came to understand, wasn't weakness. It was hormones. That realisation became Beyondbmi, an Irish medical start-up that closed a €525,000 seed round in December 2022 to bring a new model of obesity treatment to market.
The company grew out of University College Dublin's innovation ecosystem, built around a team that includes obesity scientists Alex Miras and Carel Le Roux, clinical nutritionist Werd Al-Najim, and product designer Peter Lumley alongside Treacy. Their platform pairs GLP-1 agonist drugs — originally developed for type 2 diabetes, now recognised for their effect on the brain's appetite centres — with personalised nutritional therapy and regular clinical coaching. In US trials in 2021, patients on this combined approach lost an average of 15 percent of their body weight over just over a year.
The ideological stakes are as significant as the clinical ones. Beyondbmi explicitly rejects the decades-long cultural consensus that weight is a matter of discipline. That framing, the founders argue, was never medically sound — and its failure has carried a quiet psychological toll, with people internalising long-term weight regain as personal inadequacy rather than biological reality.
Patients who join the platform will receive detailed health assessments, personalised plans, monthly video consultations with clinicians, and quarterly clinical reviews, all trackable through a proprietary app. The funding round drew investors from senior ranks of Irish business and finance, and was oversubscribed — a signal of confidence in both the science and the timing. With the global obesity drug market forecast to surpass $50 billion annually by 2030, Beyondbmi is betting that what patients need isn't just a prescription, but the clinical understanding and human support to make it mean something.
Harriet Treacy is a doctor who has spent years watching patients blame themselves for weight they couldn't lose. She'd see them in her clinic—people with high blood pressure, diabetes, infertility—and realize their bodies were working against them in ways they didn't understand. The hunger they felt wasn't a character flaw. It was biology. That observation became the seed for Beyondbmi, an Irish medical start-up that just closed a €525,000 funding round to reshape how obesity gets treated.
The company emerged from University College Dublin's innovation hub as a collaboration between Treacy, product designer Peter Lumley, obesity scientists Alex Miras and Carel Le Roux, and clinical nutritionist Werd Al-Najim. Their platform does something straightforward but novel: it combines prescription medications with nutritional therapy and one-to-one coaching. The drugs—a class called GLP-1 agonists, originally developed for type 2 diabetes—work on the brain's appetite regulation centers. Combined with behavioral support and dietary guidance informed by the latest obesity science, the approach has shown real results. Clinical trials in the United States in 2021 found patients lost an average of 15 percent of their body weight over just over a year.
What makes Beyondbmi's framing matter is what it rejects. For decades, weight loss advice has boiled down to willpower: eat less, move more. Research has shown this approach fails most people over the long term, and the failure carries a psychological cost. People internalize it as personal weakness. Treacy's point is sharper: that framing was always wrong. Obesity isn't a moral problem. It's a medical one, rooted in hormonal and biological systems that can now be addressed with actual medicine.
The funding round closed in December 2022 and was oversubscribed, drawing investors including Ergo chairman John Purdy, KPMG partner Eoghan Quigley, CKS Finance founder Conor Sheahan, and Grant Thornton's head of corporate finance Paddy Dillon. The capital will go toward launching the platform and gathering evidence of its effectiveness in the Irish market. Patients who sign up will get a detailed health assessment, personalized weight management plans, monthly video coaching sessions with clinicians, and a clinical review every three months. They can track their progress through a proprietary app and platform.
The timing is significant. Ireland's obesity rates have reached epidemic proportions by World Health Organisation standards, and globally, the pharmaceutical industry is racing to develop and market GLP-1 drugs for weight loss. JP Morgan forecasts the obesity drug market alone will be worth more than $50 billion annually by 2030. Beyondbmi is positioning itself as an early mover in a sector that's about to expand rapidly—not just selling drugs, but building the clinical infrastructure and behavioral support that makes them work. The company's bet is that patients want more than a prescription. They want to understand what's happening to their bodies and have professional guidance as they change.
Notable Quotes
For too long, hunger associated with excess fat has been treated as a willpower issue, causing untold harm to people who internalize treatment failure as personal or moral failure.— Harriet Treacy, CEO of Beyondbmi
The Hearth Conversation Another angle on the story
Why does Beyondbmi matter if the drugs already exist? Couldn't patients just ask their doctor for a GLP-1 injection?
The drugs are one piece. Most doctors aren't trained to prescribe them for weight loss, and patients don't have anywhere to go for the nutritional therapy and coaching that makes the drugs actually work. Beyondbmi is building the whole system.
So it's not about the science being new—it's about delivery?
Exactly. The science is new enough, but the real insight is older. Treacy spent years watching patients blame themselves for something their bodies were doing to them. She's building a place where that shame doesn't exist.
The 15 percent weight loss figure—is that significant?
For most people trying to lose weight, it's substantial. And it happened over about a year with clinical support, not crash dieting. That's the kind of result that tends to stick.
Why does the framing matter so much? Isn't it just marketing?
It's not marketing. It's the difference between a patient thinking they failed and a patient understanding their body has a treatable condition. That changes whether they keep trying.
What's the risk here?
That the drugs work but the coaching doesn't scale, or that it becomes expensive enough that only wealthy people can afford it. The market projection is huge—$50 billion by 2030—but that doesn't mean everyone gets access.